Market News

7 min read | Updated on November 17, 2026, 08:20 IST
SUMMARY
Shares of Urban Company could be in focus after the company opened its qualified institutional placement (QIP) issue on November 16 to raise funds from institutional investors. The company has fixed the floor price at ₹161.03 per equity share and may offer a discount of up to 5% on the floor price.

The GIFT NIFTY futures suggest that the NIFTY50 index will open 122 points lower. Image: Shutterstock
The domestic equity market is expected to open mildly lower on Tuesday, November 17. The GIFT NIFTY futures suggest that the NIFTY50 index will open 29 points lower.
The approval, following a 45-day expedited review, will allow US-based investors, including institutional investors, hedge funds and asset managers, to gain exposure to India's banking sector or hedge their positions through BANKEX futures. The development is expected to widen BSE's access to global investors and potentially improve liquidity and trading depth in its derivatives segment.
The move could affect the competitiveness of Indian steel exports to the European Union (EU). However, the actual financial impact on domestic steelmakers will depend on their exposure to the products covered by the investigation and their ability to pass on the additional costs.
The company has fixed the floor price at ₹161.03 per equity share and may offer a discount of up to 5% on the floor price.
The final issue price will be determined in consultation with the book-running lead managers. The QIP follows approval from the company's board and shareholders.
The proposed stake sale will be undertaken by four promoter entities — Paritosh Kumar, Ashish Garg, Paritosh Kumar Garg HUF and Ashish Garg & Sons HUF.
The sale is scheduled to begin on November 17 and continue until November 24, 2026, or completion of the transaction, whichever is earlier. The promoters and promoter group held a combined 78.44% stake in the company as of November 16.
Retail revenue increased 25%, while same-store sales growth (SSSG) stood at 17%. Diamond jewellery revenue grew 26%, while the company added 10 showrooms during the period.
The automaker earlier said it was taking a conservative view of demand beyond October because of a high base in the previous year and saw the potential for high single-digit growth for the M&HCV segment, with a slightly better outlook for the LCV segment.
Now for the year, we do think that it (growth) will be double-digit, Agarwal told investors on Monday.
“We think that it could go to mid-teen kind of a growth for the whole year for the industry, especially MHCV,” he said.
This outlook comes after stronger-than-expected sales in October.
In a statement, Adani Green Energy Ltd (AGEL) said the 1,500-MW project in Maharashtra had secured the requisite statutory approvals before construction began.
"No component of the Tarali Pumped Storage Project falls within any notified Protected Area and no forest land is involved in the project," it said.
The company said it had received a no-forest-land certificate on January 23, 2024, and obtained the necessary land-use permissions and statutory no-objection certificates from the competent authorities.
The statement comes amid controversy over allegations that the Adani Group's renewable energy arm reduced the declared cost of the Tarali project from ₹5,675 crore to ₹56.75 crore to lower its mandatory wildlife conservation contribution.
The strike has been called by the United Forum of IDBI Officers and Employees (UFIOE), which has demanded that the government and Life Insurance Corporation of India (LIC) withdraw the proposed stake sale.
The unions had earlier staged a two-day nationwide strike this month and have warned of intensifying their agitation, including an indefinite strike, if their demands are not met.
The drug is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.
As per the agreement, Mankind Pharma will make China-based Betta Pharmaceuticals an upfront payment, potential development and sales milestone payments, and royalty payments on the annual net sales of Ensartinib in India, the company said in a statement.
Mankind Pharma will be granted an exclusive licence to develop, manufacture, register, and commercialise Ensartinib in India, subject to the terms and conditions of the licence agreement, it said.
The wind energy solutions arm of Adani New Industries Ltd (ANIL) has also secured certification for its MWL185-5.0 MW wind turbine platform from WindGuard Certification GmbH, an independent German wind turbine testing and certification body, clearing the way for serial production.
The 91.2-metre blades are the longest wind turbine blades manufactured in the country, the company said in a statement.
Developed for the MWL 185-5.0 MW platform, they will be used on a turbine featuring a 185-metre rotor diameter, the largest in India, and a hub height of 140 metres. The rotor sweeps nearly 26,600 square metres, equivalent to more than three and a half standard football pitches, the wholly-owned subsidiary of Adani Enterprises said.
The airline, which introduced IndiGoStretch in November 2024, currently has a dual-class configuration -- economy and business -- in more than 65 of its narrow-body aircraft.
"The continued expansion also reflects evolving customer expectations and the rising demand for differentiated, premium travel experiences," the airline said in a statement.
From December 1, IndiGo will also offer IndiGoStretch, the business product, on Mumbai-Male flights. At present, over 4,000 IndiGoStretch seats are available across 12 domestic and 24 international routes.
The airline's Chief Strategy Officer Aloke Singh said India's travel market is evolving rapidly.
Related News
About The Author

Next Story